Danish Cannabis Company Stenocare To Launch 'Innovative' Medical Marijuana Oil In Germany

A publicly traded Danish medical marijuana operator Stenocare and German cannabis-focused pharma company ADREXpharma are ready to deliver a new and innovative medical cannabis oil for German patients.

The companies obtained approval to sell new medical marijuana oil in Germany, with first sales expected in the fourth quarter of 2024.

"Our Astrum 10-10 oil was first approved for sales in Australia and now we are adding Germany as the second market,"CEO of Stenocare, Thomas Skovlund Schnegelsberg stated. "In our opinion, the new Astrum product is truly groundbreaking for the entire industry of medical cannabis and for the German patients. In short, our new oil technology address key challenges in the industry of medical cannabis: 1) It doubles the uptake of cannabinoid, 2) It delivers a uniform uptake in the blood across individuals, 3) the maximum concentration of the drug is reached in half the time, and, finally, 4) it can be delivered in the body with higher uniformity regardless of food consumption."

The new product is a THC-CBD 10-10 oil in a 30 ml bottle, branded "Astrum," and the company has worldwide exclusivity for this patented oil technology.

Stenocare Astrum oil is based on innovative technology, that has the potential to increase the cannabinoid's bioavailability in patients' blood. According to the company, the oil addresses a well-known challenge with dosing medicine and securing consistent uptake of the active ingredients in the blood. With the Astrum product, Stenocare has completed a pharmacokinetic (PK) study in dogs that documented two important parameters in the lymphatic system that can improve the bioavailability:

• Parameter 1 – uptake in the blood: According to the PK-study, Astrum improves uptake in the blood with a factor 2.6 compared to a reference MCT-oil product in the market. Low and inconsistent uptake of the drug in the blood across patients is a well-known challenge in the pharma industry, that applies to most drugs.
• Parameter2 –timetomaxeffect: According to the PK study, the Stenocare Astrum product reduces time from dosing to max effect from 2-4 hours to just 1 hour.

"Even though bioavailability has been a key challenge for a long time in the medical cannabis industry, it is our experience that real data from a pharmacokinetic study regarding the challenge has not been available with a commercially available product. This puts Stenocare in a very strong position to be a first-mover in the next generation of medical cannabis oil products, that has the potential to revolutionize the market," Schnegelsberg added.

Read Next:

• German Cannabis Producer DEMECAN Receives Cultivation License Under Legalization Program, Sees Strong Revenue Growth (Updated)

Photo: Courtesy of OMfotovideocontent on Shutterstock